BioCentury | Jan 8, 2021
Finance

More strategics pile into Dutch early-stage investor BGV’s largest-ever fund

...investments already, of which one has so far been disclosed: an €18.5 million series B round in Citryll B.V....
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...“Bischofberger Revisits Gilead Castoff” ). Eric Meldrum and Paul-Peter Tak have joined the board of Citryll B.V....
BioCentury | Jul 3, 2019
Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

...ADCs) in Phase I-III testing. Citryll raises €15M series A from Chinese and Dutch investors Citryll B.V....
...L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). Elizabeth S. Eaton, Staff Writer Calliditas Therapeutics AB Citryll B.V. Jiangsu...
BioCentury | May 12, 2016
Targets & Mechanisms

Another shot at the flu

...few weeks." Antibodies that deplete neutrophils or target NETs may also represent new flu therapeutics. Citryll B.V....
...develop a caspase-1 inhibitor. Companies and Institutions Mentioned Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Citryll B.V....
BioCentury | Jul 9, 2015
Product R&D

Downstream without a NET

...have fewer side effects than PAD inhibitors already in development. Last month, ModiQuest spun out Citryll B.V....
...the normal function of PAD enzymes, and so have a decreased likehood for adverse effects," Citryll...
...fibrosis. Citryll has an exclusive option to license the IP portfolio. Companies and Institutions Mentioned Citryll B.V....
Items per page:
1 - 5 of 5
BioCentury | Jan 8, 2021
Finance

More strategics pile into Dutch early-stage investor BGV’s largest-ever fund

...investments already, of which one has so far been disclosed: an €18.5 million series B round in Citryll B.V....
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...“Bischofberger Revisits Gilead Castoff” ). Eric Meldrum and Paul-Peter Tak have joined the board of Citryll B.V....
BioCentury | Jul 3, 2019
Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

...ADCs) in Phase I-III testing. Citryll raises €15M series A from Chinese and Dutch investors Citryll B.V....
...L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). Elizabeth S. Eaton, Staff Writer Calliditas Therapeutics AB Citryll B.V. Jiangsu...
BioCentury | May 12, 2016
Targets & Mechanisms

Another shot at the flu

...few weeks." Antibodies that deplete neutrophils or target NETs may also represent new flu therapeutics. Citryll B.V....
...develop a caspase-1 inhibitor. Companies and Institutions Mentioned Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Citryll B.V....
BioCentury | Jul 9, 2015
Product R&D

Downstream without a NET

...have fewer side effects than PAD inhibitors already in development. Last month, ModiQuest spun out Citryll B.V....
...the normal function of PAD enzymes, and so have a decreased likehood for adverse effects," Citryll...
...fibrosis. Citryll has an exclusive option to license the IP portfolio. Companies and Institutions Mentioned Citryll B.V....
Items per page:
1 - 5 of 5